Exhibit 10.5
Certain confidential portions of this Exhibit were omitted by means of blackout
of the text (the "Xxxx"). This Exhibit has been filed separately with the
Secretary of the Securities and Exchange Commission without the Xxxx pursuant to
the Company's Application for Order Granting Confidential Treatment pursuant to
Rule 406 under the Securities Act of 1933, as amended.
Innovative Drug Delivery Systems, Inc.
September 22, 2000
CONFIDENTiAL
Xx. Xxxxxx X. Xxxxx Xx,, Division President
West Pharmaceutical Services, Inc.
000 Xxxxxx Xxxxx
Xxxxxxxxx, XX 00000
Re: Letter Agreement
Dear Don:
This letter shall serve as our agreement that Section 4.1 of the License
Agreement between West Pharmaceutical Services, Inc., its wholly owned
subsidiary West Pharmaceutical Services Drug Delivery & Clinical Research Centre
Ltd. and Innovative Drug Delivery Systems, Inc. is hereby amended in its
entirety to read as follows:
4.1 License Fees. IDDS shall pay to West the amount of $*** on or before
September 27, 2000.
If this is acceptable to you, kindly execute this Letter Agreement where
appropriate and return a copy to me at your earliest convenience.
Thank you.
Sincerely,
Xxxx X. Xxxxxx, M.D.
Chairman
WEST PHARMACEUTICAL SERVICES, INC.
By: /s/ Xxxxxx X. Xxxxx Xx.
----------------------------------------------
Xxxxxx X. Xxxxx Xx., Division President,
Drug Delivery Systems
WEST PHARMACEUTICAL SERVICES DRUG DELIVERY &
CLINICAL RESEARCH CENTRE LTD.
By: /s/ Xxxxxx X. Xxxxx Xx., Chairman
----------------------------------------------
Xxxxxx X. Xxxxx Xx., Chairman
000 Xxxxxxx Xxxxxx 00xx Xxxxx Xxx Xxxx, XX 00000
Tel: 000-000-0000 Fax: 000-000-0000
*** Represents material which has been omitted pursuant to an Application for
Order Granting Confidential Treatment and filed separately with the
Commission.
